Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neuropilin-1: A feasible link between liver pathologies and COVID-19
Aitor Benedicto, Iñigo García-Kamiruaga, Beatriz Arteta
World Journal of Gastroenterology (2021) Vol. 27, Iss. 24, pp. 3516-3529
Open Access | Times Cited: 21

Showing 21 citing articles:

Animal models for COVID-19: advances, gaps and perspectives
Changfa Fan, Yong Wu, Rui Xiong, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 81
COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity
Kenneth Lundström, Altijana Hromić‐Jahjefendić, Esma Bilajac, et al.
Cellular Signalling (2022) Vol. 101, pp. 110495-110495
Open Access | Times Cited: 30
The spike of SARS-CoV-2 promotes metabolic rewiring in hepatocytes
María Mercado-Gómez, Endika Prieto‐Fernández, Naroa Goikoetxea‐Usandizaga, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 23
USP9X-mediated NRP1 deubiquitination promotes liver fibrosis by activating hepatic stellate cells
Jinqiu Zhao, Jie Bai, Fengling Peng, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 13
COVID-19 and hepatic injury: Diversity and risk assessment
Fares E.M. Ali, Mostafa K Abd El-Aziz, Mahmoud Ali, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 3, pp. 425-449
Open Access | Times Cited: 12
The potential role of COVID-19 in progression, chemo-resistance, and tumor recurrence of oral squamous cell carcinoma (OSCC)
Ali Norouzi, Mahsa Liaghat, Maryam Bakhtiyari, et al.
Oral Oncology (2023) Vol. 144, pp. 106483-106483
Open Access | Times Cited: 11
Is neuropilin-1 the neuroimmune initiator of multi-system hyperinflammation in COVID-19?
Kiarash Saleki, Parsa Alijanizadeh, Abbas Azadmehr
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115558-115558
Open Access | Times Cited: 9
Cardiac Fibrosis Is a Risk Factor for Severe COVID-19
Julian Mustroph, Julian Hupf, Maria J. Baier, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 18
Liver, NAFLD and COVID-19
Carlotta Hoffmann, Philipp A. Gerber, Claudia Cavelti‐Weder, et al.
Hormone and Metabolic Research (2022) Vol. 54, Iss. 08, pp. 522-531
Open Access | Times Cited: 14
Soluble Neuropilin-1 Is Elevated in Sepsis and Correlates with Organ Dysfunction and Long-Term Mortality in Critical Illness
Philipp Hohlstein, Eileen Schumacher, Samira Abu Jhaisha, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5438-5438
Open Access | Times Cited: 2
Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma
Maria Guarino, Valentina Cossiga, Mario Capasso, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 15, pp. 4475-4475
Open Access | Times Cited: 9
Reversal of fibrosis and portal hypertension by Empagliflozin treatment of CCl4-induced liver fibrosis: Emphasis on gal-1/NRP-1/TGF-β and gal-1/NRP-1/VEGFR2 pathways
Ashraf A. Noah, Nesrine S. El-Mezayen, Samar O. El-Ganainy, et al.
European Journal of Pharmacology (2023) Vol. 959, pp. 176066-176066
Closed Access | Times Cited: 5
Target and drug predictions for SARS-CoV-2 infection in hepatocellular carcinoma patients
Luhong Wang, Yinan Ding, Chuanyong Zhang, et al.
PLoS ONE (2022) Vol. 17, Iss. 5, pp. e0269249-e0269249
Open Access | Times Cited: 6
Neuropilin Is a New Player in the Pathogenesis of COVID-19
О. А. Гомазков
Neurochemical Journal (2022) Vol. 16, Iss. 2, pp. 130-135
Open Access | Times Cited: 4
Sars-Cov2 Induced Biochemical Mechanisms in Liver Damage and Intestinal Lesions
Л. В. Спирина, Vladimir Masunov, Denis Dyakov, et al.
Indian Journal of Clinical Biochemistry (2022) Vol. 38, Iss. 4, pp. 437-446
Open Access | Times Cited: 3
Exploring potential therapeutic strategy for hepatocellular carcinoma and COVID-19 using bioinformatics analysis
Jiayan Tang, Zaiyong Yang, Huotang Qin, et al.
Egyptian Journal of Medical Human Genetics (2024) Vol. 25, Iss. 1
Open Access
IGSF1: a biomarker for predicting prognosis, immunotherapy response, and drug candidates in COVID-19 combined hepatocellular carcinoma
Yuanhui Guo, Baixuan Shen, Chaoxuan Lou, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access
COVID‐19‐associated liver injury: Adding fuel to the flame
Yingqian Wang, Min Shen, Yujia Li, et al.
Cell Biochemistry and Function (2023) Vol. 41, Iss. 8, pp. 1076-1092
Closed Access | Times Cited: 1
Association between Liver Function Indicators, Immunoglobulins, and Toll-like Receptors and Neuropilin-1 Expression in Patients with COVID-19
Salma A. El Kazafy, Amr E. Ahmed, Yasser Fouad, et al.
(2022)
Open Access | Times Cited: 2
SARS-CoV2 Induced Biochemical Mechanisms in Liver Damage and Intestinal Lesions.
Л. В. Спирина, Vladimir Masunov, Denis Dyakov, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 1
Patients with Hepatitis C Undergoing Direct-Acting Antiviral Treatment Have a Lower SARS-CoV-2 Infection Rate
Chin‐Wen Hsu, Wan-Wen Yang, Chia-Yi Hou, et al.
Life (2023) Vol. 13, Iss. 12, pp. 2326-2326
Open Access
Page 1

Scroll to top